SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending due to a significant after-hours drop following its earnings report, despite an EPS beat, as revenue concerns and increased capital expenditures spooked investors. The community is actively discussing the implications of the results on Oracle's debt and future growth, particularly in the AI space, with some questioning the company's long-term viability while others see a buying opportunity amidst the volatility.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday surge, sparking discussions about potential short squeezes and after-hours momentum. The stock's volatile price action and frequent trading halts have captivated community attention, with some comparing it to previous high-flying, low-float stocks. Traders are actively debating whether to hold overnight for further gains or take profits amidst the volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war for Warner Bros. Discovery (WBD), with community discussions focused on whether Netflix will increase its offer or walk away; a Paramount bid could allow Netflix to collect a termination fee. Some investors worry about the debt Netflix would incur if it wins the bidding war, while others speculate about political motivations affecting the deal.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's upcoming earnings report and its potential in the AI landscape. While some express concerns about competition from AI and other platforms, others highlight Adobe's established position and potential for growth, emphasizing its AI integration and buyback program.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group ($MIGI) is trending due to increasing interest in its infrastructure growth and expansion into AI and GPU services, differentiating it from typical miners. Community members are actively discussing the stock's low float and potential for a significant short squeeze, with some eyeing price targets between $12 and $40 if catalysts emerge. Traders are also anticipating potential news from an upcoming conference presentation.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending following the approval of a Designated Contract Market (DCM) license from the CFTC, allowing it to launch prediction markets. The community is discussing the potential for a short squeeze and comparing Gemini's prospects to other players in the prediction market space. Some investors see this as a bullish catalyst, while others express skepticism given GEMI's performance since its IPO.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to a U.S. patent allowance for its EVM301 series, sparking discussions of a potential short squeeze given the stock's low float; community members are weighing the IP news against the company's history of dilution. Some traders are also speculating about a potential settlement with AbbVie, which could boost the stock.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys ($SNPS) is trending after a significant investment from Nvidia, fueling optimism around AI-driven chip design and engineering; the community is closely watching whether this partnership marks a turning point for the stock, which experienced a notable drop after its recent earnings report, and many are hoping this investment will lead to new all-time highs. Some investors are also closely monitoring the impact of potential restrictions on semiconductor software exports to China, a key market for Synopsys.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking significant community discussion about its potential impact and speculation of a short squeeze given the stock's low float. Bullish sentiment is fueled by the anticipation of upcoming news and technical indicators suggesting further upward movement, though some traders caution about potential dilution. The community is actively debating price targets and whether the stock can sustain its gains.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to strong earnings, a recent acquisition, and increased price targets from analysts, driving positive after-hours movement. The community is excited about the company's growth, particularly its partnerships and expanding presence in the defense and intelligence sectors. Discussions revolve around the potential for all-time highs and a continued bullish outlook for this space-based data provider.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed Announces Grant of New Use Patents for the combination...

Galmed Issues CEO Letter to Shareholders

Galmed Issues CEO Letter to Shareholders Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel, Dec. 1, 2025 TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd...

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...

<ul class="summary-bullets"><li>Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.</li><li>The company plans to begin Phase 1b trials in early 2026 as key Stivarga patents near expiration.</li><li>Stocktwits users focused on possible dilution, SEC filings, and the timing of upcoming earnings.</li></ul>Galmed Pharmaceuticals shares&nbsp;rose on Monday, following four sessions of losses, after the company reported top-line results showing that a three-drug combination of Aramchol, Stivarga and Metformin significantly improved tumor-cell killing in gastrointestinal cancers.The stock closed up 1% at $1.05 before slipping 4.6% in after-hours trading.<h2 class="st-heading-2">Top-Line Results Highlight Triple-Drug Effect</h2>Galmed said the regimen of Aramchol, Stivarga and Metformin demonstrated a significant synergistic effect, improving tumor-cell killing both in vivo and in vitro. The company said the combination&nbsp;could be developed as a fixed-dose therapy that could strengthen the effect of Stivarga, Bayer’s top-selling cancer drug.According to the company, the combination may serve as a life-cycle IP strategy for Stivarga as key patents expire in Europe in August 2028 and in the U.S. in July 2032. Two new U.S. patent applications have been submitted.Galmed said the Aramchol-Stivarga combination is expected to enter Phase 1b clinical trials in early 2026 for metastatic colorectal cancer, hepatocellular carcinoma and cholangiocarcinoma, with a planned expansion cohort including Metformin.<h2 class="st-heading-2">Study Builds On Prior Findings</h2>An earlier May study reported that Aramchol enhanced the efficacy of regorafenib in gastrointestinal cancer models. In that study, Aramchol&nbsp;enhanced the breakdown of cellular material triggered by regorafenib and affected several cell-signaling pathways linked to tumor growth. The combination also reduced tumor growth in liver cancer models without harming normal tissue.The newly announced results include additional data on&nbsp;the use of Aramchol in combination with regorafenib and Metformin. The study reported that Aramchol showed anti-tumor activity on its own and when&nbsp;combined with the other two drugs, and that the three-drug combination produced a reinforcing effect, supporting further development as a combined treatment.<h2 class="st-heading-2">Clinical Path Ahead</h2>Allen Baharaff said a fixed-dose combination with Aramchol “could potentially become a life-cycle IP strategy for regorafenib to help delay the generic competition.”Baharaff said the company is preparing to initiate its Phase 1b study at VCU Massey Comprehensive Cancer Center in early 2026. He added that positive findings could support accelerated development of Aramchol across three gastrointestinal cancer indications and expand the company’s pipeline.<h2 class="st-heading-2">Stocktwits Users Flag Possible Dilution</h2>On Stocktwits, retail sentiment for Galmed was ‘extremely bullish’ amid a 12,950% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/glmd_ss_jpg_a183d03fe6.webp" alt="glmd ss.jpg" width="968" height="143"><figcaption>GLMD sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “Now let's wait for SEC filing. Crossed my fingers. I will tell you, if no dilution SEC is filed today after market close or before market opens, then get ready for another run and this would be epic run”<stembedurl>https://stocktwits.com/madan_shatri/message/636516948</stembedurl>Another user commented that they anticipated earnings “any day” and suggested the stock might attempt “a runup” before a potential offering.<stembedurl>https://stocktwits.com/Jonsie/message/636511939</stembedurl>Galmed’s stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galmed Pharmaceuticals logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks

Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.

Equity

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Pharmaceuticals (GLMD) shares rose sharply on Tuesday after the company reported positive preclinical data showing that its experimental drug Aramchol enhances the effectiveness of Regorafenib in liver and colon cancer models.Following the announcement, Galmed's stock rose by 10.6%, closing at $1.46 per share.&nbsp;According to the company, Aramchol improved the anti-tumor activity of Regorafenib — a multi-kinase inhibitor approved for liver and colorectal cancers — in both in-vitro and in-vivo settings.&nbsp;The combination also activated ATM and AMPK pathways while inhibiting mTORC1 and mTORC2, mechanisms known to play roles in cancer cell survival.Aramchol was also shown to work in combination with other kinase inhibitors like Sorafenib and Lenvatinib, though Regorafenib exhibited the strongest synergistic effects.&nbsp;The dual treatment suppressed tumor growth in hepatoma models without causing toxicity to normal tissues, the company said.Retail sentiment spiked following the update.&nbsp;On Stocktwits, message volume surged 4,480% over 24 hours, with sentiment marked as ‘extremely bullish.’Some retail investors suggested the stock could double from a previous $1.31 entry level.&nbsp;<stembedurl>https://stocktwits.com/debbiekatz/message/613719065</stembedurl>Others speculated the price could climb to the $2.50–$3.00 range, reflecting confidence ahead of the next trading session.<stembedurl>https://stocktwits.com/ZCOCSTOCK/message/613738896</stembedurl>Galmed said it expects to initiate a Phase 1b trial of Aramchol in combination with Regorafenib by the fourth quarter of 2025.The oncology update comes on the heels of another strategic development.&nbsp;Last week, Galmed signed a binding term sheet with Entomus s.r.o. for the licensing of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation.&nbsp;The technology enables sublingual absorption of peptides such as GLP-1, a key target in metabolic disorders.&nbsp;A definitive agreement outlining milestones and royalty terms is expected within 90 days.Shares of Galmed have fallen 56% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RBC said Medicaid spending was politically harder to unwind than the Journal suggested, adding that many small and rural hospitals depend on these payments to stay afloat. | Image source: Getty Images

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology PR Newswire TEL AVIV, Israel, Sept. 25, 2024...

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GLMD News

GLMDGalmed Pharmaceuticals Ltd